Meds & Biologics
Deciding between Stelara and Humira is one of the most common choices Crohn's patients face when starting biologic therapy or looking for an alternative after losing response to a first-line drug. Both medications are well-studied, both have years of real-world data, and both can achieve durable remission. They work through different immune pathways, have different dosing schedules, and have different safety profiles. Thanks to a head-to-head trial called SEAVUE, there is now direct evidence to guide the comparison. This guide walks through what patients should know when weighing stelara vs humira crohn's.
Two Different Mechanisms of Action
Humira (adalimumab) is a tumor necrosis factor (TNF) blocker. It neutralizes TNF-alpha, a cytokine that drives much of the inflammation in Crohn's disease. Stelara (ustekinumab) works further up the inflammatory cascade. It binds the p40 subunit shared by interleukin-12 and interleukin-23, blocking both cytokines from activating immune cells that cause gut inflammation. The practical result of this ustekinumab vs adalimumab mechanism difference is that Stelara is more selective in what it suppresses, while Humira has a broader anti-inflammatory effect. That distinction matters for side effect profiles, for patients with psoriasis or psoriatic arthritis as comorbidities, and for how each drug performs in patients who have already tried another biologic.
The SEAVUE Trial: A Rare Head-to-Head
Most biologic comparisons rely on indirect evidence, but the SEAVUE trial directly compared ustekinumab and adalimumab as first-line therapy in biologic-naive Crohn's patients. Published in The Lancet in 2022, the phase 3b superiority trial randomized 386 adults with moderate-to-severe Crohn's disease to one of the two drugs and followed them for 52 weeks. At week 52, 65% of ustekinumab patients and 61% of adalimumab patients were in clinical remission, with no statistically significant difference between groups, according to Sands et al.. Corticosteroid-free remission rates were similarly close at 61% and 57%. In biologic-naive patients, the efficacy data points to a near tie.
Early Response and Endoscopic Healing
Humira showed a modest early edge in SEAVUE. At week 16, a slightly higher proportion of adalimumab patients reached clinical remission, and Humira performed marginally better on some endoscopic remission measures in that early window, per HCPLive's trial summary. By week 52 that gap had closed. For patients who need fast symptom control, this early response data sometimes shifts the decision toward Humira, though most gastroenterologists weigh the 52-week outcomes more heavily because long-term remission is the treatment goal. If symptoms do not improve within the first few months, both drugs allow dose escalation or a switch to another class.
Safety and Tolerability
Safety was the area where Stelara separated itself in SEAVUE. Serious infections occurred in 2% of ustekinumab patients and 3% of adalimumab patients. Overall infection rates were 34% for Stelara and 40% for Humira. The more notable difference was in tolerability: 6.3% of Stelara patients discontinued because of adverse events versus 11.3% of Humira patients. For stelara vs humira side effects, the class-wide risks of Humira include injection-site reactions, increased risk of serious infection, reactivation of latent tuberculosis or hepatitis B, and a small increase in lymphoma risk. Stelara carries a lower infection signal in trial data and does not require routine combination therapy with an immunomodulator, which simplifies long-term management for many patients.
Dosing and Administration
Humira is a subcutaneous injection you give yourself. After induction of 160 mg on day 1, 80 mg on day 15, maintenance is 40 mg every other week, according to AbbVie prescribing information. Stelara uses a different approach. Induction is a single weight-based intravenous infusion at a hospital or infusion center, followed by subcutaneous injections of 90 mg every 8 weeks at home, per Janssen's Stelara dosing information. A newer subcutaneous induction option is also available for some patients. The every-8-week maintenance schedule is a significant convenience advantage over Humira's every-other-week cadence, though patients who tolerate self-injection well may prefer the flexibility of Humira's shorter intervals.
Biologic-Experienced Patients and Switching From Humira
SEAVUE enrolled biologic-naive patients, which means its findings do not directly answer whether Stelara works in people who have already failed an anti-TNF. For that question, the IM-UNITI program showed Stelara produced meaningful remission in patients who had previously failed a TNF blocker, which is why switching from humira to stelara is a common sequence. Real-world cohorts suggest response rates in anti-TNF experienced patients are lower than in naive patients with either drug, but ustekinumab tends to retain more of its efficacy after anti-TNF failure than a second anti-TNF would. If Humira has lost effect and your GI is choosing a second biologic, the mechanism switch to IL-12/23 blockade is supported by trial and registry data.
Which Biologic Fits Your Situation
For a biologic-naive patient with uncomplicated moderate-to-severe Crohn's, SEAVUE shows you can reasonably start with either drug. Stelara may fit better if you want a less frequent maintenance schedule, have a concurrent plaque psoriasis diagnosis, or are concerned about long-term infection risk. Humira may fit better if cost or insurance favors adalimumab biosimilars, if you want all-subcutaneous administration without an infusion center visit, or if faster onset of response is a priority. If you have already failed an anti-TNF, the IL-12/23 vs anti-TNF crohn's decision usually leans toward Stelara. Ask your GI how response will be measured at the standard assessment points (typically week 16 to 26 for both drugs), what to do if symptoms persist or return, and whether therapeutic drug monitoring will be part of your follow-up plan. Keeping a simple log of stool frequency, urgency, pain, and extraintestinal symptoms between visits gives your care team the data they need to recognize a partial response early.